Michael L. Watkins

2.1k total citations
31 papers, 1.5k citations indexed

About

Michael L. Watkins is a scholar working on Pulmonary and Respiratory Medicine, Physiology and General Health Professions. According to data from OpenAlex, Michael L. Watkins has authored 31 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 10 papers in Physiology and 3 papers in General Health Professions. Recurrent topics in Michael L. Watkins's work include Chronic Obstructive Pulmonary Disease (COPD) Research (22 papers), Respiratory Support and Mechanisms (9 papers) and Asthma and respiratory diseases (9 papers). Michael L. Watkins is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (22 papers), Respiratory Support and Mechanisms (9 papers) and Asthma and respiratory diseases (9 papers). Michael L. Watkins collaborates with scholars based in United States, United Kingdom and Netherlands. Michael L. Watkins's co-authors include Emiel F.�M. Wouters, Jørgen Vestbo, Stephen I. Rennard, Ruth Tal‐Singer, Nicholas Locantore, Peter M.A. Calverley, Bartolomé R. Celli, Víctor Pinto-Plata, Lisa Edwards and Courtney Crim and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, Antimicrobial Agents and Chemotherapy and The American Journal of Cardiology.

In The Last Decade

Michael L. Watkins

26 papers receiving 1.5k citations

Peers

Countries citing papers authored by Michael L. Watkins

Since Specialization

Citations

This map shows the geographic impact of Michael L. Watkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael L. Watkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael L. Watkins more than expected).

Fields of papers citing papers by Michael L. Watkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael L. Watkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael L. Watkins. The network helps show where Michael L. Watkins may publish in the future.

Co-authorship network of co-authors of Michael L. Watkins

This figure shows the co-authorship network connecting the top 25 collaborators of Michael L. Watkins. A scholar is included among the top collaborators of Michael L. Watkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael L. Watkins. Michael L. Watkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1 study of the safety, tolerability, and pharmacokinetics of a synthetic macrocyclic peptide antibiotic (BRII-693) in healthy adult participants 2024 ·Antimicrobial Agents and Chemotherapy ·Michael L. Watkins, (unknown), David C. Griffith, Jeffery S. Loutit, David M. Margolis, (unknown)	0
2	Apparatuses and methods of determining if a person operating equipment is experiencing an elevated cognitive load 2023 ·OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) ·Michael L. Watkins	0
3	A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD 2020 ·BMC Pulmonary Medicine ·Courtney Crim, Mark H. Gotfried, Selwyn Spangenthal, Michael L. Watkins, Amanda Emmett, C. Gerald Crawford, Charlotte A. Baidoo, Ramiro Castro‐Santamaria	9
4	<p>Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD</p> 2019 ·International Journal of COPD ·Courtney Crim, Michael L. Watkins, Eric Bateman, Gregory Feldman, Isabelle Schenkenberger, Edward Kerwin, C. Gerald Crawford, (unknown), (unknown), Charlotte A. Baidoo, Ramiro Castro‐Santamaria	6
5	Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial 2019 ·Respiratory Research ·François Maltais, Leif Bjermer, Edward Kerwin, Paul Jones, Michael L. Watkins, Lee Tombs, Ian Naya, I. Boucot, David A. Lipson, Chris Compton, (unknown), Claus Vogelmeier	76
6	Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD 2016 ·BMJ Open Respiratory Research ·James L. Kreindler, Michael L. Watkins, Sally Lettis, Ruth Tal‐Singer, Nicholas Locantore	32
7	Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients 2014 ·Respiratory Medicine ·Mark T. Dransfield, Gregory Feldman, Phillip E. Korenblat, Craig LaForce, Nicholas Locantore, Massimo Pistolesi, Michael L. Watkins, Courtney Crim, Fernando J. Martínez	27
8	Shortness of Breath with Daily Activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary disease 2013 ·BMJ Open ·Michael L. Watkins, Teresa K. Wilcox, Maggie Tabberer, Jean Brooks, James F. Donohue, Antonio Anzueto, (unknown), Courtney Crim	18
9	Item selection, reliability and validity of the Shortness of Breath with Daily Activities (SOBDA) questionnaire: a new outcome measure for evaluating dyspnea in chronic obstructive pulmonary disease 2013 ·Health and Quality of Life Outcomes ·Teresa K. Wilcox, Wen‐Hung Chen, Kellee Howard, Ingela Wiklund, Jean Brooks, Michael L. Watkins, (unknown), Maggie Tabberer, Courtney Crim	14
10	Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease 2012 ·American Journal of Respiratory and Critical Care Medicine ·Michael I. Polkey, Martijn A. Spruit, Lisa Edwards, Michael L. Watkins, Víctor Pinto-Plata, Jørgen Vestbo, Peter M.A. Calverley, Ruth Tal‐Singer, Àlvar Agustí, Per Bakke, Harvey O. Coxson, David A. Lomas, William MacNee, Stephen I. Rennard, Edwin K. Silverman, Bruce E. Miller, Courtney Crim, Julie Yates, Emiel F.�M. Wouters, Bartolomé R. Celli	239
11	Dysregulated adipokine metabolism in chronic obstructive pulmonary disease 2012 ·European Journal of Clinical Investigation ·Marie‐Kathrin Breyer, Erica P.A. Rutten, Nicholas Locantore, Michael L. Watkins, Bruce E. Miller, Emiel F.�M. Wouters, (unknown)	39
12	Development of the Shortness of Breath with Daily Activities Questionnaire (SOBDA) 2012 ·Value in Health ·Kellee Howard, Pamela Berry, Jennifer Petrillo, Ingela Wiklund, Laurie Roberts, Michael L. Watkins, Courtney Crim, Teresa K. Wilcox	15
13	Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease 2011 ·Journal of the American Medical Directors Association ·Martijn A. Spruit, Michael I. Polkey, Bartolomé R. Celli, Lisa Edwards, Michael L. Watkins, Víctor Pinto-Plata, Jørgen Vestbo, Peter M.A. Calverley, Ruth Tal‐Singer, Àlvar Agustí, Harvey O. Coxson, David A. Lomas, William MacNee, Stephen I. Rennard, Edwin K. Silverman, Courtney Crim, Julie Yates, Emiel F.�M. Wouters	179
14	Determinants of Depression in the ECLIPSE Chronic Obstructive Pulmonary Disease Cohort 2010 ·American Journal of Respiratory and Critical Care Medicine ·Nicola A. Hanania, Hana Müllerová, Nicholas Locantore, Jørgen Vestbo, Michael L. Watkins, Emiel F.�M. Wouters, Stephen I. Rennard, Amir Sharafkhaneh	240
15	Determinants of poor 6-min walking distance in patients with COPD: The ECLIPSE cohort 2010 ·Respiratory Medicine ·Martijn A. Spruit, Michael L. Watkins, Lisa Edwards, Jørgen Vestbo, Peter M.A. Calverley, Víctor Pinto-Plata, Bartolomé R. Celli, Ruth Tal‐Singer, Emiel F.�M. Wouters	161
16	Evaluation of an ambulatory system for the quantification of cough frequency in patients with chronic obstructive pulmonary disease 2005 ·PubMed ·Michael Coyle, D. Barry Keenan, Linda S. Henderson, Michael L. Watkins, Brett Haumann, David Mayleben, Michael G. Wilson	97
17	Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis 2004 ·Annals of Allergy Asthma & Immunology ·Michael T. Halpern, Jordana K. Schmier, Maria D. Van Kerkhove, Michael L. Watkins, Chris Kalberg	45
18	Vasopressin: a new target for the treatment of heart failure 2003 ·American Heart Journal ·Craig R. Lee, Michael L. Watkins, J. Herbert Patterson, Wendy A. Gattis, Christopher M. O’Connor, Mihai Gheorghiade, Kirkwood F. Adams	161
19	Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia 2001 ·The American Journal of Cardiology ·James M. McKenney, L. McCormick, (unknown), Donald M. Black, Michael L. Watkins	101
20	Double-masked, randomized, parallel-group comparison of cefaclor af and cefaclor in the treatment of acute bacterial sinusitis 1997 ·Current Therapeutic Research ·(unknown), Michael L. Watkins, Don Johns	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact